for Health Care Providers
HIV Meds Quarterly
- Rosiglitazone and Heart Disease
- Antipsychotics and Sudden Cardiac Death
- New Pharmacokinetic Booster on the Horizon
- Interleukin-2: No Clinical Benefit
- Raltegravir Substitution for Lopinavir/Ritonavir (SWITCHMRK Study)
- Abacavir and Myocardial Infarction Risk: Additional Data
Darunavir: Traditional approval
In January, the U.S. Food and Drug Administration granted traditional approval for the use of the integrase inhibitor raltegravir in treatment-experienced adults. It had been granted accelerated approval in 2007. As with other antiretroviral agents, it must be used in combination ARV regimens.
New Guidelines: Adult OI prevention and treatment
Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. March 24, 2009. MMWR 2009; 58 (early release) pp 1-198.
Updated: Pediatric ARV guidelines
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, François-Xavier Bagnoud Center at the University of Medicine and Dentistry of New Jersey (UMDNJ), Health Resources and Services Administration (HRSA), and National Institutes of Health (NIH). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Updated February 23, 2009.
Updated: Perinatal guidelines
Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, April 29, 2009.